PO.PS01.07 · 人群科学

界定shelterin复合体基因中的癌症风险胚系变异——一项基因组优先分析

Defining cancer risk germline variants in shelterin complex genes - a genome-first analysis

海报缩略图:界定shelterin复合体基因中的癌症风险胚系变异——一项基因组优先分析
编号 3597 展板 15 时间 4/20 02:00–05:00 区域 Section 35 主讲 Hasset Nurelegne, BS
分会场 Genetic Epidemiology 1: GxE, GWAS, Polygenic Risk Scores, and Post-GWAS
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Hasset Nurelegne, Akanksha Nagarkar, Jung Kim, Douglas Stewart, Sharon Savage, Kelvin C. De Andrade

National Cancer Institute, Bethesda, MD

摘要 Abstract

中文摘要
背景:shelterin复合体(由ACD、POT1、TERF1、TERF2、TERF2IP和TINF2编码)对端粒维持和染色体稳定性至关重要。某些shelterin基因中的致病性或可能致病性(P/LP)胚系变异可导致端粒生物学疾病以及伴长端粒的癌症易感性。迄今为止,相关研究一直集中于临床确诊的家系。基因组优先方法从与电子健康记录相链接的群体规模测序数据库中识别携带罕见P/LP变异的个体,从而能够更好地估计变异患病率和癌症风险。 方法:我们评估了ACD、TERF1、TERF2、TERF2IP和TINF2中的罕见(次要等位基因频率<1%)P/LP胚系变异。分析了来自UK Biobank(UKB)(N=469,578)和Geisinger DiscovEHR队列(N=216,361)的外显子组和表型数据。使用AutoGVP和文献回顾对变异进行分类。分别使用logistic回归模型评估携带者与非携带者中的癌症患病率和风险,并对出生年份、性别、吸烟状况、饮酒量、体重指数和遗传学确定的血统进行校正。 结果:我们识别出1,200名(UKB中784名,Geisinger中416名)携带shelterin复合体基因P/LP胚系变异的个体。shelterin变异的患病率在UKB中为1:1,886至1:39,132,在Geisinger中为1:1,157至1:24,040,其中ACD和TINF2的估计值最高,TERF2最低。在ACD中,一个此前与癌症相关的变异(c.488A>G,p.Asn163Ser)占所有ACD携带者的49.3%。在UKB中,TINF2携带者发生黑色素瘤(OR 5.33(1.93-14.70);p=0.015)、内分泌癌(OR 25.30(9.16-69.87);p<0.001)和间皮瘤(OR 18.38(2.47-137.02);p=0.036)的风险显著增加,且总体癌症发病年龄早于非携带者(p=0.0036)。在Geisinger中,TINF2与软组织(包括心脏)癌症(OR 6.76(1.65-27.60);p=0.01)、肝脏/胆管癌(OR 3.28(1.03-10.50);p=0.05)和脑/神经系统癌症(OR 5.19(1.89-14.20);p<0.001)风险增加相关。在Geisinger中,携带c.488A>G的ACD携带者发生眼及眼眶癌的风险增加(OR 15.27(2.10-111.00);p=0.007),尽管仅有一名携带者。携带TERF1、TERF2和TERF2IP变异个体中的癌症事件数量不足以进行统计学分析。 结论:在Geisinger中,罕见P/LP shelterin基因变异的患病率总体上高于UKB,反映了该队列临床富集的特性。TINF2的变异具有最强的癌症关联。有必要对更年轻的队列进行纵向研究,以完善shelterin复合体基因相关的患病率估计和癌症风险。
查看英文原文 English abstract
Background : The shelterin complex (encoded by ACD, POT1, TERF1, TERF2, TERF2IP, andTINF2) is essential for telomere maintenance and chromosome stability. Pathogenic or likelypathogenic (P/LP) germline variants in some shelterin genes cause telomere biology disorders aswell as cancer predisposition with long telomeres. To date, studies have focused on clinicallyascertained families. Genome-first approaches identify individuals with rare P/LP variants frompopulation-scale sequencing databases linked to electronic health records, enabling better estimates of variant prevalence and cancer risk. Methods : We assessed rare (minor allele frequency<1%) P/LP germline variants in ACD,TERF1, TERF2, TERF2IP, and TINF2. Exome and phenotype data were analyzed from UKBiobank (UKB) (N=469,578) and Geisinger DiscovEHR cohort (N=216,361). Variants wereclassified using AutoGVP and literature review. Cancer prevalence and risk in carriers versusnoncarriers were evaluated using logistic regression models, respectively, adjusted for year ofbirth, sex, smoking status, alcohol intake, body mass index, and genetically determined ancestry. Results : We identified 1,200 individuals (784 in UKB and 416 in Geisinger) with P/LP germlinevariants in shelterin complex genes. The prevalence of shelterin variants ranged from 1:1,886 to1:39,132 in UKB and 1:1,157 to 1:24,040 in Geisinger, ACD and TINF2 had the highestestimates and TERF2 the lowest. In ACD, a variant previously associated with cancer(c.488A>G, p.Asn163Ser) accounted for 49.3% of all ACD carriers. In UKB, TINF2 carriers hadsignificantly increased risk for melanoma (OR 5.33 (1.93-14.70); p=0.015), endocrine cancers(OR 25.30 (9.16-69.87); p<0.001), and mesothelioma (OR 18.38 (2.47-137.02); p=0.036) anddemonstrated overall earlier ages at cancer onset than noncarriers (p=0.0036). In Geisinger,TINF2 was associated with increased risk of cancers of soft tissue including heart (OR 6.76 (1.65-27.60); p=0.01), liver/ bile duct (OR 3.28 (1.03-10.50); p=0.05), and brain/nervous system(OR 5.19 (1.89-14.20); p<0.001). In Geisinger, ACD carriers with c.488A>G had an increasedrisk of eye and orbit cancers (OR 15.27 (2.10-111.00); p=0.007), although there was only onecarrier. The number of cancer events among individuals with TERF1, TERF2, and TERF2IPvariants was insufficient for statistical analyses. Conclusion : In Geisinger, prevalence of rare P/LP shelterin gene variants was generally higherthan in UKB, reflecting the clinically enriched nature of that cohort. TINF2 had variants with thestrongest cancer associations. Longitudinal studies of younger cohorts are warranted to refineprevalence estimates and cancer risk associated with shelterin complex genes.
利益披露 Disclosure
H. Nurelegne, None.. A. Nagarkar, None.. J. Kim, None.. D. Stewart, None.. S. Savage, None.. K. C. De Andrade, None.

← 返回 AACR 2026 检索